Save this technology
close
Save to Existing Project
Save to a New Project
New Chemical Entities and Innovative Therapeutic Targets
Zambon SpA Italy flag Italy
Abstract ID:
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases.
Contact Salvatore Sturniolo
RE:
Participants
You

Zambon's R&D core competences range from hit-to-lead optimization up to full drug development. Its Lead Optimization Unit is capable to quickly bridge the gap between hit discovery and pre-clinical development and to reduce the risk of failures in clinical development. Zambon's R&D wants to become a valuable partner for all those Drug Discovery companies that want to add value to their lead molecules and see their candidate drugs enter riskless into development.

Type of Business Relationship Sought
<p>Companies having proprietary hits/lead compounds for innovative targets or proprietary targets and screening capabilities, will find a dynamic group capable to either optimize existing compounds or discover new hits. Zambon business model is based on collaboration aiming at bringing values to all partners. Roles and responsibilities can be flexibly arranged to obtain a successful and well-balanced relationship among partners.</p>
FEATURED
Last Updated Feb 2017
Technology Type THERAPEUTIC
Phase of Development EARLY STAGE
CORPORATION

Opportunity Contact